Want to see AU:CSL full AI Analyst Report?
CSL Stock Chart & Stats
AU$114.22
AU$2.17(1.90%)
At close: 4:00 PM EDT
AU$114.22
AU$2.17(1.90%)
Day’s Range― - ―
52-Week RangeAU$90.00 - AU$228.30
Previous CloseN/A
Volume639.54K
Average Volume (3M)974.43K
Market Cap
AU$75.58B
Enterprise ValueAU$70.67K
Total Cash (Recent Filing)AU$1.51B
Total Debt (Recent Filing)AU$10.89B
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Feb 09, 2027EPS Estimate
5.76Next Dividend Ex-DateN/A
Dividend Yield2.53%
Share Statistics
EPS (TTM)-5.29
Shares Outstanding478,912,000
10 Day Avg. Volume1,091,561
30 Day Avg. Volume974,433
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.74
Price to Sales (P/S)3.45
P/FCF Ratio18.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$163.77Price Target Upside43.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)6.24
Revenue Forecast (FY)AU$15.67B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation Supports Reinvestment And Shareholder ReturnsConsistently positive operating cash flow gives CSL flexibility to fund capital investment, product development and shareholder distributions, even during a difficult earnings year. This supports financial resilience while management addresses portfolio challenges.
Transformation Program Is Delivering Material, Scalable SavingsSavings delivered ahead of plan can provide a recurring offset to cost inflation and weaker product performance. The planned reinvestment of part of the savings into commercial and R&D activity may also strengthen CSL’s long-term growth platform.
Behring’s Immunoglobulin Franchise And Specialty Launches Support GrowthImproving immunoglobulin momentum in CSL’s largest franchise, combined with successful specialty launches, supports durable demand from serious and rare-disease patients. Scale, regulated manufacturing and commercial reach may help sustain growth as newer products mature.
Bears Say
Large Impairments And Statutory Loss Weaken Earnings QualityThe scale of impairments signals that parts of the acquired or existing portfolio have materially lower economic value than previously expected. The statutory loss and reduced equity cushion constrain confidence in earnings quality and balance-sheet flexibility.
Vifor Faces Structural Portfolio ErosionGeneric competition, loss of regulatory authorization and the ending of Velphoro’s TDAPA benefit create persistent pressure on Vifor’s revenue base. A projected 25% decline makes portfolio replacement and impairment recovery important execution challenges.
Albumin Pressure In China And Weaker Margins Weigh On ProfitabilityChina’s cost-containment measures and lower albumin market value can pressure pricing and mix beyond a single quarter. Combined with the Behring margin contraction, this may limit profit conversion even if plasma volumes and overall demand remain resilient.
CSL News
CSL FAQ
What was CSL’s price range in the past 12 months?
CSL lowest share price was AU$90.00 and its highest was AU$228.30 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is AU$75.58B.
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Feb 09, 2027 which is in 172 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Aug 17, 2026. The company reported AU$3.378 earnings per share for the quarter, beating the consensus estimate of AU$3.328 by AU$0.049.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of AU$1.81 which represents an annual dividend yield of 2.53%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 5.76.
How many shares outstanding does CSL have?
CSL has 478,912,000 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of AU$3.378 in its last earnings report, beating expectations of AU$3.328. Following the earnings report the stock price went up 17.251%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in AU:CSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$163.77 (43.38% Upside)
AU$163.77 (43.38% Upside)
Blogger Sentiment
Bullish
AU:CSL Sentiment 83%
Sector Average 61%
Sector Average 61%
Insider Transactions
Bought Shares
Worth AU$457.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.80%
12-Months-Change
Fundamentals
Return on Equity
2.53%
Trailing 12-Months
Asset Growth
-14.61%
Trailing 12-Months
Company Description
CSL
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
CSL Company Deck
CSL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of stabilization and operational progress (strong cash flow, ahead-of-plan transformation savings, Ig momentum in H2, successful new product launches and Seqirus share gains) but was overshadowed by very large impairments, a statutory net loss, and significant, structural headwinds in Vifor (anticipated ~25% revenue decline) plus continued pressure on albumin. While management has a clear remediation plan and delivered early positive operational signs, the scale and persistence of the portfolio and impairment issues materially weaken near-term financial prospects.View all AU:CSL earnings summariesCSL Stock 12 Month Forecast
Average Price Target
AU$163.77
▲(43.38% Upside)
Technical Analysis
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―